-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As of September 2021, Covid-19 caused by SARS-CoV-2 has caused 230 million infections and 4.
Infection FDA recently researchers announced the REGEN-COV treat new crown pneumonia Phase III clinical study results
This study is a phase III clinical study.
Of the 1355 patients in the REGEN-COV 2400-mg group, 18 (1.
Of the 1355 patients in the REGEN-COV 2400-mg group, 18 (1.
Reduced risk of hospitalization or death after REGEN-COV treatment
After REGEN-COV treatment, the risk of hospitalization or death is reduced.REGEN-COV treatment can reduce the risk of Covid-19-related hospitalization or death, can quickly relieve symptoms and reduce the viral load of patients
Original source:
David M.
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
Leave a message here